论文部分内容阅读
目的 :观察平阳霉素 (BLMA5)局部注射治疗顽固性残留淋巴瘤结节的临床疗效。方法 :38例患者 ,其中瘤内注射组 (下称瘤内组 ) 2 6例 ,以BLMA58mg ,加生理盐水 1～ 3ml,行瘤内注射。瘤旁注射组 (下称瘤旁组 ) 12例 ,同剂量瘤周注射。用药前 10分钟 ,二组均肌注地塞米松 (DXM ) 5～ 10mg。上述方法 ,2次 /周 ,连续 2周。结果 :瘤内注射组 ,CR 17例 ,PR 5例 ,RR 84.6 % ;瘤旁注射组 12例 ,仅 1例PR ,RR 8.3% ,两组比较 ,具显著性差异 (P <0 .0 1)。各组毒副反应均较轻。结论 :提示BLMA5瘤内注射是顽固性残留淋巴瘤结节的一种较好的治疗方法。
Objective: To observe the clinical efficacy of local injection of Pingyangmycin (BLMA5) for refractory lymphoma nodules. Methods: 38 patients, of which intratumoral injection group (hereinafter referred to as intratumoral group) 26 cases, were injected intratumorally with BLMA 58mg plus normal saline 1 ~ 3ml. Paratumor injection group (hereinafter referred to as paraneoplastic group) in 12 cases, the same dose of peritumoral injection. Ten minutes before treatment, both groups were intramuscularly infused with dexamethasone (DXM) 5 to 10 mg. The above method, 2 times / week, for 2 weeks. Results: Intratumoral injection group, CR 17 cases, PR 5 cases, RR 84.6%; paratumor injection group 12 cases, only 1 case of PR, RR 8.3%, there was a significant difference between the two groups (P <0. ). The toxicity of each group was lighter. Conclusion : It is suggested that BLMA5 intratumoral injection is a better treatment for refractory lymphoma nodules.